This article is more than 5 years old. Information may no longer be current.

Top 6 recent developments in schizophrenia research

There has been an abundance of recently published studies exploring schizophrenia treatments and risk factors, comorbidities and interventions.

Below are the top 6 most popular developments in schizophrenia research published on Healio.com/Psychiatry within the past few months.

Cariprazine safely, effectively treats negative schizophrenia symptoms

Researchers enrolled 461 individuals with predominant, negative symptoms of schizophrenia in a multinational, randomized, double-blind risperidone-controlled, parallel group clinical trial to evaluate the efficacy, safety and tolerability of cariprazine. Read more

FDA approves Aristada for schizophrenia

The FDA recently approved Aristada, an extended-release injection drug, to treat schizophrenia in adults. Safety and efficacy of the newly approved drug was demonstrated in a 12-week clinical trial that included 622 study participants. Read more

FDA addresses concerns regarding clozapine, severe neutropenia

The FDA recently altered requirements for monitoring, prescribing, dispensing and receiving clozapine to address continued safety concerns about severe neutropenia. Read more

Certain birth factors associated with schizophrenia risk in patients with genetic condition

To determine if perinatal complications were associated with schizophrenia expression in individuals with 22q11.2 deletion syndrome, Bassett and colleagues analyzed the birth weight and prematurity of 123 patients with the disorder. Read more

Research shows increased risk for diabetes among certain individuals with psychosis, taking antipsychotics

To assess how age, family history of diabetes and current antipsychotic treatment affected risk for diabetes, researchers analyzed data from the 2010 Australian National Survey of Psychosis for 1,155 individuals with psychosis aged 18 to 64 years. Read more

Stigma of mental illness may increase depression, anxiety among those at high-risk for psychosis

To evaluate the effects of stigma among individuals with a clinical high-risk for psychosis, researchers assessed labeling-related measures including stereotype awareness or self-stigma and negative emotions (ie, shame) among 38 patients at clinical high-risk for psychosis. Read more